Conference Coverage
Latest News
Aug 28, 2026 | News
This Month in Derm: August 2026 Podcasts
Study Highlights Hidden Inflammation Beyond Visible Lesions in Dissecting Cellulitis of the Scalp
Aug 28, 2026
QRX003 Meets Primary Endpoint in Netherton Syndrome Trial
Aug 28, 2026
Hair Transplantation Expands Beyond the Scalp: Eyebrows, Beard, and Beyond
Aug 27, 2026
Dermatology Times August 2026 Print Recap
Aug 27, 2026
Videos
Advertisement
Shorts
0:34
Can We Actually Prevent Skin Cancer?
10 hours ago
by
Shawn Demehri, MD, PhD
0:56
Brepocitinib Approved for Dermatomyositis
10 hours ago
by
Kaitlyn Bader, Assistant Managing Editor
0:38
Why We Need 'Field Treatment' for Skin Cancer
11 hours ago
by
Shawn Demehri, MD, PhD
0:19
A Quick Trick to Decompress When You're Stressed
a day ago
by
Buchi Neita, MCMSc, PA-C
0:38
What Young Cancer Researchers Are Up Against
2 days ago
by
Stephanie Kauffman
0:38
The Crisis Facing Young Cancer Researchers
3 days ago
by
Stephanie Kauffman
0:36
How Long Does It Take to See Hair Growth Results?
3 days ago
by
Heather C. Woolery-Lloyd, MD
0:18
We Found a 37% Increase In Hair Growth Rate
4 days ago
by
Heather C. Woolery-Lloyd, MD
0:46
Why You Should Treat PWCMs As Early As Possible
5 days ago
by
Kristen Marie Kelly, MD, FAAD(+1 more)
0:19
A Simple Strategy for Managing Stress
6 days ago
by
Buchi Neita, MCMSc, PA-C
GEP-Guided Treatment for Melanoma & SCC Management
New Insights in Management of Moderate Hidradenitis Suppurativa
Discover Dermatology Times NP/PA Connect™!
Personalizing Treatment for Difficult Atopic Dermatitis Cases
Connect With Dermatology Times® Wherever You Scroll
Podcasts
Dermatology Times Digital Edition
Learn more about the in-depth topics covered in the August 2026 issue of Dermatology Times.
Experts map referral pathways and team-based immunotherapy care for advanced cutaneous squamous cell carcinoma, tackling toxicity and follow-up gaps.
Experts weigh checkpoint inhibitors for advanced cutaneous squamous cell carcinoma, highlighting real-world safety, immunotherapy referrals, and where cosibelimab may belong.
Shawna Jones, PA-C, shares a road map to aesthetics, emphasizing clinical judgment, anatomy, patient trust, safety, and lifelong learning.
Multidisciplinary experts rethink advanced cutaneous squamous cell carcinoma care, weighing immunotherapy options, trial data limits, adverse events, and smoother dermatology-oncology referrals.
The latest DermView custom video series explored how molecular tools are reshaping management decisions in cutaneous squamous cell carcinoma.
The investigational anti–IL-13 monoclonal antibody could change how dermatologists think about biologic dosing in moderate to severe AD.
Learn how private equity rollups reshape dermatology—EBITDA deals, MSOs, and the real tradeoffs for owners, PAs, and new grads.
Shanna Miranti, MPAS, PA-C, explores how fertility treatments can affect skin and hair, including acne, melasma, and hair loss, and offers guidance for patient care.
New research shows dermatologists continue to back daily sunscreen to prevent aging and skin cancer, debunking viral myths and spotlighting safer new filters coming to the US.
Continuing Medical Education
All News
Advertisement
Advertisement
The FDA approval, based on phase 3 VALOR trial data, makes brepocitinib the first targeted therapy specifically indicated for dermatomyositis.
Experts map referral pathways and team-based immunotherapy care for advanced cutaneous squamous cell carcinoma, tackling toxicity and follow-up gaps.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of August.
Verrica Pharmaceuticals has completed enrollment in COVE-2, its first pivotal phase 3 trial of YCANTH for common warts, with topline data expected in the first quarter of 2027.
Experts weigh checkpoint inhibitors for advanced cutaneous squamous cell carcinoma, highlighting real-world safety, immunotherapy referrals, and where cosibelimab may belong.
Europe’s dermatology apps boom, but most lack clinical validation, CE/GDPR transparency, and inclusive AI training, raising safety and reliability concerns for patients.
A secondary analysis of the phase 3 VALOR trial found brepocitinib 30 mg nearly doubled remission-level skin responses and improved itch as early as week 4 compared with placebo.
Shawna Jones, PA-C, shares a road map to aesthetics, emphasizing clinical judgment, anatomy, patient trust, safety, and lifelong learning.
This review of the latest dermatological studies includes insights on multimodal imaging for rosacea evaluation, growth in pediatric AD patients, botulinum toxin for post-acne sequelae, and more.
Rezpegaldesleukin improved EASI, itch, and other outcomes in phase 2b REZOLVE-AD, supporting continued phase 3 development.
Advertisement
Multidisciplinary experts rethink advanced cutaneous squamous cell carcinoma care, weighing immunotherapy options, trial data limits, adverse events, and smoother dermatology-oncology referrals.
New trials show oral collagen boosts hydration, elasticity and barrier strength in weeks—while wrinkle and dermal density claims remain unproven.
The latest DermView custom video series explored how molecular tools are reshaping management decisions in cutaneous squamous cell carcinoma.
Real-world data show ruxolitinib cream improves facial vitiligo in 3 months, boosting quality of life and imaging-confirmed repigmentation.
New trials show oral psoriasis drugs rival biologics, expand care across ages, and spotlight systemic risks—plus the ongoing fight for access. Read our exclusive recap for PsO Action Month.
Advertisement
Advertisement
Trending on Dermatology Times
1
Hair Transplantation Expands Beyond the Scalp: Eyebrows, Beard, and Beyond
2
FDA Approves Brepocitinib for Dermatomyositis
3
The Aesthetic Edge: August 2026
4
The Multibillion-Dollar Molecule: How Zumilokibart’s Phase 2 Success Sparked AbbVie’s Acquisition
5